Wall Street Teacher (a pseudonym) worked on Wall Street for several years in the fixed income area and now teaches and writes on financial topics (primarily regulation and markets). Current interests include the psychology of financial markets, the origins of chemistry/physics, synthetic biology, human evolution,siege engines, antique prints, truffles, old cameras, debunking "short and distort" hit pieces, picking RJ Kirk's brain, Battlefield III (we all have our vices) and horology.
I'm a value investor focused on buying companies trading below the intrinsic value.
I've a back ground in engineering & finance. I'm also a Chartered Financial Analyst. I did my MBA from Emory University's Goizueta School of Business
Chris is the founder of a new Austin-based startup in the beta testing phase.
He is entrepreneur with significant experience researching and evaluating a broad spectrum of subjects, including: technology, investments and private equity opportunities.
Previously he served as Director of Marketing & Technology at Axion Capital Management / Axion Opportunity Fund. A top ranked boutique absolute return fund with a global perspective.
Graycell Advisors (GraycellAdvisors.com and PrudentBiotech.com) publishes growth stock newsletters. The quantitative, algorithm-driven model portfolios have a track record of significantly and consistently outperforming the market. The articles on Market Outlook, Smallcap market segment and Biotech sector, are written by Tarun Chandra, CFA, who has experience as an Equity Analyst on the Sellside and Buyside, and experience in Corporate Strategy and Finance working on Main Street. Fundamentals drive valuations. Technicals assist in timing. Stocks mentioned in the report may be now or in the past, part of the growth portfolios recommended by Graycell Advisors and related entities.
I am a medical professional that enjoys investing in biotech stocks. I take long positions and may dabble in options. I have a particular interest in biotechs with an ophthalmic (eye) focus as that is where I have developed the greatest expertise over my career and research. I hope over time to share some of my professional insights with those of the Seeking Alpha community in order to help them make more informed investing decisions. I expect to learn a lot from others as well.
I am long the following biotechs at this time: GILD, OPHT, CRMD, ACAD, RLYP, HALO, TGTX, APHB, ZIOP.
I am advising everyone to avoid: OHRP
bio-seeker...of the next biotech breakthrough. Emerging small cap biotech, cancer immunotherapy, PD-1, CD47, RNAi, CAR-T, KIR/NK.
Investing decisions based on information derived from credible sources...clinical trial data, research papers and independent analysis by those who are qualified to analyze... always skeptical of sell side analysis. Never invest based on a single SA article. Always consider the bio of SA authors... 95% can be ignored altogether based on lack of expertise.